Cullinan Oncology Inc.

8.6100.00Vol 116.76K1Y Perf -29.71%
Nov 29th, 2023 16:00 DELAYED
BID7.91 ASK9.27
Open8.64 Previous Close8.61
Pre-Market- After-Market8.61
 - -  - -%
Target Price
30.50 
Analyst Rating
Strong Buy 1.00
Potential %
254.24 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-67/-67/-93 
Value Ranking
★★★★★     69.65
Insiders Value % 3/6/12 mo.
-81/-81/-96 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-79/-79/-93 
Income Ranking
 —    -
Price Range Ratio 52W %
13.90 
Earnings Rating
Market Cap368.34M 
Earnings Date
13th Nov 2023
Alpha-0.04 Standard Deviation0.11
Beta0.18 

Today's Price Range

8.389.18

52W Range

7.7813.74

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
1.53%
1 Month
2.14%
3 Months
-21.01%
6 Months
-14.33%
1 Year
-29.71%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CGEM8.610.00000.00
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
21.20
21.50
0.01
0.01
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-358.70
-358.40
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.99-0.8217.17
Q01 2023-0.84-1.42-69.05
Q04 2022-0.65-0.599.23
Q03 2022-0.97-0.5444.33
Q02 20225.47-2.20-140.22
Q01 2022-0.61-0.2755.74
Q04 2021-0.47-0.74-57.45
Q03 2021-0.42-0.404.76
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.90
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume116.76K
Shares Outstanding42.78K
Shares Float26.58M
Trades Count2.75K
Dollar Volume1.01M
Avg. Volume118.14K
Avg. Weekly Volume79.91K
Avg. Monthly Volume121.02K
Avg. Quarterly Volume153.50K

Cullinan Oncology Inc. (NASDAQ: CGEM) stock closed at 8.61 per share at the end of the most recent trading day (a 1.18% change compared to the prior day closing price) with a volume of 93.13K shares and market capitalization of 368.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 26 people. Cullinan Oncology Inc. CEO is Owen Hughes.

The one-year performance of Cullinan Oncology Inc. stock is -29.71%, while year-to-date (YTD) performance is -18.39%. CGEM stock has a five-year performance of %. Its 52-week range is between 7.782 and 13.74, which gives CGEM stock a 52-week price range ratio of 13.90%

Cullinan Oncology Inc. currently has a PE ratio of 4.90, a price-to-book (PB) ratio of 0.85, a price-to-sale (PS) ratio of 26.37, a price to cashflow ratio of -, a PEG ratio of -, a ROA of 19.70%, a ROC of 19.92% and a ROE of 20.49%. The company’s profit margin is -%, its EBITDA margin is -358.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cullinan Oncology Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.90 for the next earnings report. Cullinan Oncology Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cullinan Oncology Inc. is Strong Buy (1), with a target price of $30.5, which is +254.24% compared to the current price. The earnings rating for Cullinan Oncology Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cullinan Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cullinan Oncology Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.92, ATR14 : 0.53, CCI20 : -91.90, Chaikin Money Flow : -0.15, MACD : -0.15, Money Flow Index : 29.47, ROC : -13.38, RSI : 43.08, STOCH (14,3) : 23.94, STOCH RSI : 0.71, UO : 34.80, Williams %R : -76.06), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cullinan Oncology Inc. in the last 12-months were: Gregg Michaelson (Sold 0 shares of value $-51 600 ), Gregg Michaelson (Sold 13 498 shares of value $163 946 ), Jacquelyn L. Sumer (Sold 595 shares of value $6 559 ), Jeffrey Alan Jones (Sold 782 shares of value $8 613 ), Jeffrey Trigilio (Sold 1 115 shares of value $12 029 ), Jennifer Michaelson (Sold 652 shares of value $7 042 ), Nadim Ahmed (Sold 3 594 shares of value $37 544 ), Trigilio Jeffrey (Sold 2 579 shares of value $27 916 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cullinan Oncology Inc.

Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

CEO: Owen Hughes

Telephone: +1 617 410-4650

Address: One Main Street, Cambridge 02142, MA, US

Number of employees: 26

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

56%44%

Bearish Bullish

52%48%

 

News

Stocktwits